Active substance
Erythromycin lactobionate
- US FDA 14
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ERYTHROCIN | EQ 500MG BASE/VIAL | injectable · injection | HOSPIRA | Prescription | 24 Sep 1986 |
| ERYTHROCIN | EQ 500MG BASE/VIAL | injectable · injection | HOSPIRA | Prescription | 31 Oct 1986 |
| ERYTHROMYCIN LACTOBIONATE | EQ 500MG BASE/VIAL | injectable · injection | NEXUS | Prescription | 14 Feb 2022 |
| ERYTHROMYCIN LACTOBIONATE | EQ 500MG BASE/VIAL | injectable · injection | GLAND | Prescription | 19 Nov 2024 |
| ERYTHROCIN | EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL | injectable · injection | HOSPIRA | Discontinued | 25 Jun 1964 |
| ERYTHROMYCIN | EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL | injectable · injection | ELKINS SINN | Discontinued | 28 Mar 1985 |
| ERYTHROCIN | EQ 1GM BASE/VIAL | injectable · injection | HOSPIRA | Discontinued | 24 Sep 1986 |
| ERYTHROCIN | EQ 1GM BASE/VIAL | injectable · injection | HOSPIRA | Discontinued | 31 Oct 1986 |
| ERYTHROCIN | EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL | injectable · injection | ABBOTT | Discontinued | 4 Jan 1988 |
| ERYTHROMYCIN LACTOBIONATE | EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL | injectable · injection | BAXTER HLTHCARE | Discontinued | 9 May 1989 |
| ERYTHROMYCIN LACTOBIONATE | EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL | injectable · injection | TEVA PARENTERAL | Discontinued | 30 Jul 1993 |
| ERYTHROMYCIN LACTOBIONATE | EQ 500MG BASE/VIAL | injectable · injection | EXELA PHARMA | Discontinued | 17 Sep 2020 |
| ERYTHROMYCIN LACTOBIONATE | EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL | injectable · injection | ABRAXIS PHARM | Discontinued | |
| ERYTHROMYCIN LACTOBIONATE | EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL | injectable · injection | QUAD PHARMS | Discontinued |
Safety signals and safety-related labeling changes
- US FDA 5 Nov 2019 ERYTHROCIN — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.